Table 1.

Clinical Features of Human Pituitary Corticotroph Tumors Treated With R-Roscovitine in Primary Cell Culture

Patient Number	ACTH Reduction With R-Roscovitine Treatment, %	Clinical Features
		Age and Gender	ACTH, pg/mLa	24 Hours UFC, μg/da	Tumor Diameter, mm	Duration, yb	Prior Rx	Comorbidities
1	56 ± 2.4	16, M	98	459	5.7	3	None	DM, HTN, obesity, mood changes, myopathy, hypogonadism
2	24 ± 5.9	22, F	30	820	9	3	TSS, K, C	DM, obesity, osteoporosis
3	1.3 ± 14.5c	29, F	54	281	8	4	None	HTN, obesity
4	30 ± 1.3	73, M	296	59	28	15	TSS × 3, R	DM, HTN, obesity, CAD, hypogonadism
5	22 ± 13.1	16, F	139	661	37	5	K	DM, HTN, obesity, amenorrhea, hirsutism, acne, myopathy, anxiety
6	62 ± 20.5	33, F	44	239	4	2	None	HTN, obesity, myopathy, rash, irregular menses

Abbreviations: C, cabergoline; CAD, coronary artery disease; DM, diabetes mellitus; F, female; HTN, hypertension; K, ketoconazole; M, male; R, radiotherapy; Rx, treatment; TSS, transsphenoidal surgery; UFC, urinary free cortisol. Medium ACTH concentrations in primary cultures were measured by RIA (normalized for viable cell numbers).

^aPreoperative mean value.

^bCD duration before surgery.

^cNonsignificant (P > .05).